ArticleClinical & translational immunology2015
Adoptive T-cell immunotherapy for ganciclovir-resistant CMV disease after lung transplantation.
Article in Clinical & translational immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 154 citations in OpenAlex.
- Viral infections in solid organ transplant recipients: immunological principles and intervention strategies.American journal of translational research · 2026Review
- "Innovative diagnostics and treatments of infections in transplantation," report from the 2025Transplant international : official journal of the European Society for Organ Transplantation · 2026Article
- Adoptive T-cell therapy for virus-associated diseases.Clinical microbiology reviews · 2025Review
- Harnessing virus-specific T cells: expanding therapeutic strategies across diverse populations.Blood advances · 2025Review
- A Phase I Study Evaluating Safety and Tolerability of Viral-Specific T Cells Against BK-Virus in Adult Kidney Transplant Recipients.Journal of medical virology · 2025Article
- Compassionate access to virus-specific T cells for adoptive immunotherapy over 15 years.Nature communications · 2024Article
- EphA3 CAR T cells are effective against glioblastoma in preclinical models.Journal for immunotherapy of cancer · 2024Article
- Article
- Updates in Cytomegalovirus Prevention and Treatment in Solid Organ Transplantation.Infectious disease clinics of North America · 2023Review
- Case Report: Fatal cytomegalovirus pneumonia after CAR-T cell therapy in the long-term follow-up.Frontiers in immunology · 2023Article
- New Treatment Options for Refractory/Resistant CMV Infection.Transplant international : official journal of the European Society for Organ Transplantation · 2023Review
- Review
- CRISPR-Cas9-Edited Tacrolimus-Resistant Antiviral T Cells for Advanced Adoptive Immunotherapy in Transplant Recipients.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Article
- Is It Feasible to Use CMV-Specific T-Cell Adoptive Transfer as Treatment Against Infection in SOT Recipients?Frontiers in immunology · 2021Review
- Progress and Challenges in the Prevention, Diagnosis, and Management of Cytomegalovirus Infection in Transplantation.Clinical microbiology reviews · 2020Review
- High-intensity interval training in allogeneic adoptive T-cell immunotherapy - a big HIT?Journal of translational medicine · 2020Article
- Cytomegalovirus Infection in Solid Organ and Hematopoietic Cell Transplantation: State of the Evidence.The Journal of infectious diseases · 2020Review
- Impact of CMV Reactivation, Treatment Approaches, and Immune Reconstitution in a Nonmyeloablative Tolerance Induction Protocol in Cynomolgus Macaques.Transplantation · 2020Article
- The CD4+ T Cell Response to Human Cytomegalovirus in Healthy and Immunocompromised People.Frontiers in cellular and infection microbiology · 2020Review
- T cell repertoire remodeling following post-transplant T cell therapy coincides with clinical response.The Journal of clinical investigation · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infections with cytomegalovirus (CMV) can induce severe complications after solid organ transplantation (SOT). The prognosis for ganciclovir-resistant CMV infection and disease is particularly poor. Whereas adoptive transfer of CMV-specific T cells has emerged as a powerful tool in hematopoietic stem cell transplant patients, its translation into the SOT setting remains a significant challenge as underlying immunosuppression inhibits the virus-specific T-cell response in vivo. Here, we demonstrate successful expansion and adoptive transfer of autologous CMV-specific T cells from a seronegative recipient of a seropositive lung allograft with ganciclovir-resistant CMV disease, resulting in the long-term reconstitution of protective anti-viral immunity, CMV infection, disease-free survival and no allograft rejection.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.